Development of commercially viable enantioselective processes for HIV-1 NNRTIs.
A review of the process research and development of the quinazolinone-based HIV-1 drug candidates DPC-961 and DPC- 963 is presented. This article details the chronological evolution of the synthetic processes from the original racemic syntheses to routes that enabled the production of kilogram quantities of drug substances and the development of commercially viable processes. This review describes the process development challenges encountered during an accelerated development program.
Parsons
R L
RL
DuPont Pharmaceuticals, Chemical Process Research and Development, Chambers Works, PRF-112, Deepwater, NJ 08023, USA. rodney.l.parsons@dupontpharma.com